Analyst Price Target is 5.50
▲ +71.34% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for 23andMe in the last 3 months. The average price target is 5.50, with a high forecast of 7.00 and a low forecast of 3.00. The average price target represents a 71.34% upside from the last price of 3.21.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in 23andMe. This rating has held steady since August 2021, when it changed from a Hold consensus rating.
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.